When Product Design Becomes a Compliance Surface

The EU’s DSA findings against TikTok signal a shift from content moderation to scrutiny of engagement mechanics like infinite scroll and recommender systems, reframing product design as an auditable compliance surface.

The DHS Funding Clock Just Turned Appropriations Into an Enforcement Lever

Congress funded DHS only through mid-February, turning the budget calendar into a lever for shaping immigration enforcement expectations without passing new law or formal rules.

Medical AI Didn’t Fail the Test — It Struggled at the Human Interface

A Nature Medicine study shows that medical AI models performing well on benchmarks deliver worse outcomes when used by real people, shifting regulatory attention from model accuracy to human–AI interaction and governance design.

IDR just became a pricing audit surface

IDR under the No Surprises Act is no longer just resolving disputes. Repeated arbitration decisions are creating a cumulative evidence trail that tests whether payer pricing models are defensible at scale.

Novo vs. Hims Isn’t About Weight-Loss Drugs — It’s About When “Stopping” Stops Mattering

Novo Nordisk’s lawsuit against Hims after a GLP-1 alternative was withdrawn signals that in regulated markets, demonstrating substitute capability can trigger enforcement even when sales stop.

AI regulation is crossing a line — from rules on paper to systems you can audit

U.S. AI regulation is shifting from rules on paper to systems that can be audited, as regulators inventory their own AI use and move toward performance-based, traceable oversight.

New York just reframed prediction markets — and the risk isn’t gambling

New York’s warning on prediction markets reframes regulatory risk away from gambling labels and toward how probabilistic outputs function, influence behavior, and are relied upon in real decision contexts.

When AI Stops Being a Tool — and Starts Being Interpreted as a Duty of Care

Regulators are increasingly viewing some AI companions as behavior-shaping environments rather than neutral tools, opening a pathway for oversight under existing consumer protection and child safety frameworks.

FDA Oversight Is Losing Resolution — And Industry May Increasingly Be Expected to Close the Gap

GAO warnings that FDA oversight is constrained by data gaps and complexity suggest a quiet shift in expectations, with industry increasingly expected to supply clearer, earlier, and more continuous evidence of risk control.